文献速递垂体与肾上腺疾病

原发性醛固酮增多症患者血浆ACE2浓度与心血管结局

Circulating Plasma Concentrations of ACE2 in Primary Aldosteronism and Cardiovascular Outcomes.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

该研究纳入168例原发性醛固酮增多症(PA)患者,发现PA与原发性高血压(EH)患者血浆ACE2(pACE2)水平相似且均升高;肾上腺切除术后pACE2下降,而MRA治疗者下降不显著;靶向治疗后持续pACE2>23 ng/mL与全因死亡和心血管事件相关(HR=8.8,P=.04)。

要点

  • PA与EH患者pACE2水平相似(47.04±22.06 vs 46.73±21.06 ng/mL,P=.937)。
  • 肾上腺切除术后pACE2下降,MRA治疗者下降无统计学意义。
  • 靶向治疗后持续pACE2>23 ng/mL与全因死亡和心血管事件相关(HR=8.8,P=.04)。

核心结论

  • PA和EH患者pACE2及TMPRSS2 mRNA表达均高于血压正常人群。
  • 靶向治疗后持续pACE2>23 ng/mL与死亡和心血管事件风险相关。

研究设计与样本

  • 研究为起始观察性队列,纳入168例初发PA患者。
  • 检测外周血单核细胞中ACE2、TMPRSS2和ADAM17表达。
  • 72例单侧PA患者接受肾上腺切除术,按Primary Aldosteronism Surgery Outcome标准评估高血压完全缓解。
  • 平均随访3.29年。

主要发现

  • 初发PA与EH患者pACE2相似(47.04±22.06 vs 46.73±21.06 ng/mL;P=.937)。
  • PA患者中年龄与pACE2负相关(β=-2.15;P=.033),较高血清钾与pACE2正相关(β=2.29;P=.024)。
  • 72例手术单侧PA患者中36例(50%)达到临床完全高血压缓解。
  • 随访中手术患者pACE2下降:有高血压缓解者P<.001,无缓解者P=.006;MRA治疗的单侧PA(P=.085)和双侧PA(P=.409)下降无统计学意义。
  • 靶向治疗后持续pACE2>23 ng/mL与全因死亡和心血管事件相关(HR=8.8;P=.04)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The plasma concentrations of angiotensin-converting enzyme 2 (pACE2) has been independently associated with cardiovascular diseases. OBJECTIVE: Higher pACE2 concentrations may be found in patients with primary aldosteronism (PA) and might lead to increased cardiovascular events. METHODS: Using an inception observational cohort, we examined pACE2 among 168 incident patients with PA. The expression of ACE2, serine protease 2 (TMPRSS2), and metalloprotease 17 (ADAM17) were assessed in peripheral blood mononuclear cells. RESULTS: Incident PA and essential hypertension (EH) patients had similarly elevated pACE2 (47.04 ± 22.06 vs 46.73 ± 21.06 ng/mL; P = .937). Age was negatively (β = -2.15; P = .033) and higher serum potassium level (β = 2.29; P = .024) was positively correlated with higher pACE2 in PA patients. Clinical complete hypertension remission after adrenalectomy (Primary Aldosteronism Surgery Outcome criteria) was achieved in 36 (50%) of 72 surgically treated unilateral PA (uPA) patients. At follow-up, pACE2 decreased in surgically treated patients who had (P < .001) or had no (P = .006) hypertension remission, but the pACE2 attenuation was not statistically significant in uPA (P = .085) and bilateral PA (P = .409) administered with mineralocorticoid receptor antagonist (MRA). Persistently elevated pACE2 (> 23 ng/mL) after targeted treatments was related to all-cause mortality and cardiovascular events among PA patients (hazard ratio = 8.8; P = .04); with a mean follow-up of 3.29 years. TMPRSS2 messenger RNA (mRNA) expression was higher in uPA (P = .018) and EH (P = .038) patients than in normotensive controls; it was also decreased after adrenalectomy (P < .001). CONCLUSION: PA and EH patients had elevated pACE2 and higher expression of TMPRSS2 mRNA compared to those of normotensive population. Persistently elevated pACE2 (> 23 ng/mL) after targeted treatments was associated risk of mortality and incident cardiovascular events.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Wu VC, Peng KY, Hu YH, et al. Circulating Plasma Concentrations of ACE2 in Primary Aldosteronism and Cardiovascular Outcomes. J Clin Endocrinol Metab. 2022. PMID: 36125178. doi:10.1210/clinem/dgac539

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。